Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Strong Buy” by Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus rating of “Strong Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have issued a strong buy recommendation on the company.

Several brokerages have recently commented on ZLDPF. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th.

Zealand Pharma A/S Price Performance

Shares of ZLDPF opened at $65.28 on Friday. The firm has a market capitalization of $4.64 billion, a price-to-earnings ratio of 4.70 and a beta of 0.74. The stock’s fifty day moving average is $75.45 and its 200-day moving average is $69.28. Zealand Pharma A/S has a one year low of $49.98 and a one year high of $110.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. The company had revenue of $7.76 million for the quarter, compared to the consensus estimate of $4.54 million. Equities analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.